Genetic association between TRAIL-R1 Thr209Arg and cancer susceptibility

Scientific Reports
Peiliang GengHoujie Liang

Abstract

We aimed to determine the indecisive association between tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) Thr209Arg polymorphism and inherited susceptibility to cancer. A meta-analysis combining data on 9,517 individuals was performed to assess the association between TRAIL-R1 Thr209Arg and cancer incidence. The summary ORs with 95% CI calculated with the fixed effects model suggested that Thr209Arg was not significantly associated with cancer susceptibility (homozygous model: OR 0.98, 95% CI 0.88-1.09; heterozygous model: OR 0.95, 95% CI 0.87-1.04; allele frequency model: OR 0.99, 95% CI 0.94-1.05; dominant model: OR 0.98, 95% CI 0.91-1.05; recessive model: OR 1.01, 95% CI 0.92-1.10). Stratified analysis by ethnicity and cancer type yielded similar null associations. These statistical data suggest that Thr209Arg in exon 4 of the TRAIL-R1 gene may not represent a modifier of susceptibility to cancer.

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Apr 4, 1997·Science·G PanV M Dixit
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
May 18, 2001·Nature·G I Evan, K H Vousden
Oct 18, 2002·International Journal of Cancer. Journal International Du Cancer·Susanne SeitzSiegfried Scherneck
Dec 14, 2004·Genetic Epidemiology·Elias Zintzaras, John P A Ioannidis
Feb 16, 2005·Apoptosis : an International Journal on Programmed Cell Death·S BouralexisA Evdokiou
May 3, 2005·Gynecologic Oncology·Peter HorakMichael Krainer
May 25, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jan J KoornstraJan H Kleibeuker
Oct 13, 2006·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Bernd FrankBarbara Burwinkel
May 25, 2007·Cancer Biomarkers : Section a of Disease Markers·José I Martinez-FerrandisM-Eugenia Armengod
Jun 10, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Alison L Van DykeAnn G Schwartz
Aug 1, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Bo ChenJian-Qing Wu
Apr 13, 2011·International Journal of Cancer. Journal International Du Cancer·Michelle G DickRita K Schmutzler
Jun 28, 2011·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·R D MittalA Mandhani
May 11, 2013·Pathology Oncology Research : POR·Deniz Taştemir-KorkmazSerap Hastürk

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

STATA

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Li-Hong WangYa-Li Hu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Elisabeth G E de VriesSteven de Jong
© 2021 Meta ULC. All rights reserved